Zhejiang Jolly Pharmaceutical Co Ltd (300181) - Net Assets
Based on the latest financial reports, Zhejiang Jolly Pharmaceutical Co Ltd (300181) has net assets worth CN¥3.49 Billion CNY (≈ $511.19 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.33 Billion ≈ $780.05 Million USD) and total liabilities (CN¥1.84 Billion ≈ $268.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Zhejiang Jolly Pharmaceutical Co Ltd to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.49 Billion |
| % of Total Assets | 65.53% |
| Annual Growth Rate | 18.86% |
| 5-Year Change | 63.44% |
| 10-Year Change | 120.22% |
| Growth Volatility | 52.37 |
Zhejiang Jolly Pharmaceutical Co Ltd - Net Assets Trend (2007–2025)
This chart illustrates how Zhejiang Jolly Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See 300181 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Zhejiang Jolly Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual net assets of Zhejiang Jolly Pharmaceutical Co Ltd from 2007 to 2025. For live valuation and market cap data, see Zhejiang Jolly Pharmaceutical Co Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.24 Billion ≈ $474.31 Million |
+14.96% |
| 2024-12-31 | CN¥2.82 Billion ≈ $412.57 Million |
+1.64% |
| 2023-12-31 | CN¥2.77 Billion ≈ $405.92 Million |
+0.51% |
| 2022-12-31 | CN¥2.76 Billion ≈ $403.86 Million |
+39.16% |
| 2021-12-31 | CN¥1.98 Billion ≈ $290.21 Million |
+15.34% |
| 2020-12-31 | CN¥1.72 Billion ≈ $251.61 Million |
+22.14% |
| 2019-12-31 | CN¥1.41 Billion ≈ $206.00 Million |
+1.48% |
| 2018-12-31 | CN¥1.39 Billion ≈ $203.01 Million |
-6.92% |
| 2017-12-31 | CN¥1.49 Billion ≈ $218.09 Million |
+1.26% |
| 2016-12-31 | CN¥1.47 Billion ≈ $215.38 Million |
+2.52% |
| 2015-12-31 | CN¥1.44 Billion ≈ $210.07 Million |
+64.68% |
| 2014-12-31 | CN¥871.76 Million ≈ $127.57 Million |
+12.85% |
| 2013-12-31 | CN¥772.52 Million ≈ $113.04 Million |
+9.43% |
| 2012-12-31 | CN¥705.92 Million ≈ $103.30 Million |
+3.22% |
| 2011-12-31 | CN¥683.92 Million ≈ $100.08 Million |
+230.12% |
| 2010-12-31 | CN¥207.17 Million ≈ $30.32 Million |
+25.03% |
| 2009-12-31 | CN¥165.70 Million ≈ $24.25 Million |
+11.12% |
| 2008-12-31 | CN¥149.11 Million ≈ $21.82 Million |
+3.21% |
| 2007-12-31 | CN¥144.47 Million ≈ $21.14 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Jolly Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6407.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.00 Billion | 31.49% |
| Other Components | CN¥2.18 Billion | 68.51% |
| Total Equity | CN¥3.18 Billion | 100.00% |
Zhejiang Jolly Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Jolly Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Garden Bio-chemical High-tech Co Ltd
SHE:300401
|
$1.32 Billion |
|
Chengdu Haoneng Tech Co Ltd
SHG:603809
|
$1.32 Billion |
|
Boai NKY Pharmaceuticals Ltd
SHE:300109
|
$1.32 Billion |
|
Cheil Worldwide
KO:030000
|
$1.32 Billion |
|
Guangdong Marubi Biotechnology Co
SHG:603983
|
$1.32 Billion |
|
Lightspeed Commerce Inc
TO:LSPD
|
$1.32 Billion |
|
Sk Gas
KO:018670
|
$1.32 Billion |
|
Jiangsu Chengxing Phosph-Chemical Co Ltd
SHG:600078
|
$1.32 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Jolly Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,768,884,681 to 3,180,077,389, a change of 411,192,708 (14.9%).
- Net income of 631,933,709 contributed positively to equity growth.
- Dividend payments of 423,894,665 reduced retained earnings.
- Other comprehensive income decreased equity by 296,607,303.
- Other factors increased equity by 499,760,967.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥631.93 Million | +19.87% |
| Dividends Paid | CN¥423.89 Million | -13.33% |
| Other Comprehensive Income | CN¥-296.61 Million | -9.33% |
| Other Changes | CN¥499.76 Million | +15.72% |
| Total Change | CN¥- | 14.85% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Jolly Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.83x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 36.12x to 2.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.36 | CN¥12.83 | x |
| 2008-12-31 | CN¥0.37 | CN¥12.83 | x |
| 2009-12-31 | CN¥0.41 | CN¥12.83 | x |
| 2010-12-31 | CN¥0.51 | CN¥12.83 | x |
| 2011-12-31 | CN¥1.33 | CN¥12.83 | x |
| 2012-12-31 | CN¥1.31 | CN¥12.83 | x |
| 2013-12-31 | CN¥1.46 | CN¥12.83 | x |
| 2014-12-31 | CN¥1.48 | CN¥12.83 | x |
| 2015-12-31 | CN¥2.29 | CN¥12.83 | x |
| 2016-12-31 | CN¥2.20 | CN¥12.83 | x |
| 2017-12-31 | CN¥2.10 | CN¥12.83 | x |
| 2018-12-31 | CN¥2.12 | CN¥12.83 | x |
| 2019-12-31 | CN¥2.15 | CN¥12.83 | x |
| 2020-12-31 | CN¥2.63 | CN¥12.83 | x |
| 2021-12-31 | CN¥3.03 | CN¥12.83 | x |
| 2022-12-31 | CN¥3.85 | CN¥12.83 | x |
| 2023-12-31 | CN¥3.92 | CN¥12.83 | x |
| 2024-12-31 | CN¥3.98 | CN¥12.83 | x |
| 2025-12-31 | CN¥4.53 | CN¥12.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Jolly Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.87%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.78%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.48x
- Recent ROE (19.87%) is above the historical average (10.31%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 9.62% | 10.98% | 0.50x | 1.74x | CN¥-552.65K |
| 2008 | 11.16% | 10.09% | 0.59x | 1.88x | CN¥1.73 Million |
| 2009 | 19.06% | 14.67% | 0.72x | 1.80x | CN¥15.01 Million |
| 2010 | 20.02% | 15.79% | 0.75x | 1.68x | CN¥20.76 Million |
| 2011 | 7.45% | 18.23% | 0.33x | 1.23x | CN¥-17.46 Million |
| 2012 | 8.78% | 18.04% | 0.40x | 1.22x | CN¥-8.59 Million |
| 2013 | 10.48% | 19.31% | 0.45x | 1.22x | CN¥3.75 Million |
| 2014 | 12.84% | 20.04% | 0.44x | 1.47x | CN¥22.81 Million |
| 2015 | 6.56% | 12.64% | 0.36x | 1.43x | CN¥-44.40 Million |
| 2016 | 5.45% | 8.57% | 0.41x | 1.54x | CN¥-60.15 Million |
| 2017 | 3.33% | 6.65% | 0.32x | 1.59x | CN¥-90.33 Million |
| 2018 | 1.61% | 2.84% | 0.35x | 1.64x | CN¥-108.40 Million |
| 2019 | 1.95% | 2.81% | 0.44x | 1.56x | CN¥-105.44 Million |
| 2020 | 5.54% | 8.14% | 0.44x | 1.54x | CN¥-71.48 Million |
| 2021 | 9.73% | 12.31% | 0.53x | 1.49x | CN¥-5.00 Million |
| 2022 | 10.10% | 15.12% | 0.50x | 1.35x | CN¥2.63 Million |
| 2023 | 14.03% | 19.71% | 0.54x | 1.33x | CN¥110.06 Million |
| 2024 | 18.34% | 19.70% | 0.65x | 1.44x | CN¥230.88 Million |
| 2025 | 19.87% | 20.78% | 0.65x | 1.48x | CN¥313.93 Million |
Industry Comparison
This section compares Zhejiang Jolly Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $5,126,862,668
- Average return on equity (ROE) among peers: 6.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | CN¥3.49 Billion | 9.62% | 0.53x | $1.32 Billion |
| Zhejiang Int'L Group Co Ltd (000411) | $3.21 Billion | 10.69% | 2.51x | $732.38 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $1.98 Billion | 1.15% | 0.48x | $308.51 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $-153.68 Million | 0.00% | 0.00x | $750.55 Million |
| Hubei Guangji Pharmaceutical Co Ltd (000952) | $134.18 Million | 12.98% | 0.83x | $302.41 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $9.15 Billion | 2.09% | 0.37x | $1.73 Billion |
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | $758.22 Million | 2.72% | 0.11x | $247.30 Million |
| Sichuan Kelun Pharmaceutical Co Ltd (002422) | $29.29 Billion | 5.81% | 0.36x | $8.36 Billion |
| Chongqing Lummy Pharmaceutical (300006) | $1.65 Billion | -9.38% | 1.12x | $760.20 Million |
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) | $127.61 Million | 29.20% | 0.15x | $1.63 Billion |
About Zhejiang Jolly Pharmaceutical Co Ltd
Zhejiang Jolly Pharmaceutical Co.,LTD engages in the research, production, and marketing of Chinese medicinal products in the People's Republic of China and internationally. It offers Wuling capsule to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kid… Read more